EE04582B1 - Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis - Google Patents

Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis

Info

Publication number
EE04582B1
EE04582B1 EEP200000794A EEP200000794A EE04582B1 EE 04582 B1 EE04582 B1 EE 04582B1 EE P200000794 A EEP200000794 A EE P200000794A EE P200000794 A EEP200000794 A EE P200000794A EE 04582 B1 EE04582 B1 EE 04582B1
Authority
EE
Estonia
Prior art keywords
radiotherapy
cancer
preparation
pharmaceutical composition
protein transferase
Prior art date
Application number
EEP200000794A
Other languages
English (en)
Estonian (et)
Inventor
Franciscus Van Ginckel Robert
Joanna Floren Wim
William End David
Boudewijn Leopold Wouters Walter
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200000794A publication Critical patent/EE200000794A/xx
Publication of EE04582B1 publication Critical patent/EE04582B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
EEP200000794A 1998-07-06 1999-06-30 Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis EE04582B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98202257 1998-07-06
EP98204330 1998-12-18
PCT/EP1999/004545 WO2000001411A1 (en) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Publications (2)

Publication Number Publication Date
EE200000794A EE200000794A (et) 2002-06-17
EE04582B1 true EE04582B1 (et) 2006-02-15

Family

ID=26150503

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000794A EE04582B1 (et) 1998-07-06 1999-06-30 Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis

Country Status (30)

Country Link
US (1) US6545020B1 (es)
EP (1) EP1094839B1 (es)
JP (1) JP4530537B2 (es)
KR (1) KR100591603B1 (es)
CN (1) CN1152716C (es)
AP (1) AP1599A (es)
AT (1) ATE238811T1 (es)
AU (1) AU762423B2 (es)
BG (1) BG64941B1 (es)
BR (1) BR9911861A (es)
CA (1) CA2336624C (es)
CZ (1) CZ300968B6 (es)
DE (1) DE69907461T2 (es)
DK (1) DK1094839T3 (es)
EA (1) EA003877B1 (es)
EE (1) EE04582B1 (es)
ES (1) ES2199579T3 (es)
HR (1) HRP20000903A2 (es)
HU (1) HU229076B1 (es)
ID (1) ID26987A (es)
IL (2) IL140721A0 (es)
MY (1) MY126519A (es)
NO (1) NO328178B1 (es)
PL (1) PL193464B1 (es)
PT (1) PT1094839E (es)
SI (1) SI1094839T1 (es)
SK (1) SK284723B6 (es)
TR (1) TR200003879T2 (es)
TW (1) TW586937B (es)
WO (1) WO2000001411A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
PL193464B1 (pl) 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
SI1255537T1 (sl) * 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
JP4974437B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する6−[(置換フェニル)メチル]−キノリンおよびキナゾリン誘導体
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
DE60118225T2 (de) 2000-09-25 2007-05-03 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2002214056A1 (en) 2000-11-21 2002-06-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
JP4351445B2 (ja) 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する4−置換−キノリンおよびキナゾリン誘導体
US20040067968A1 (en) * 2000-12-27 2004-04-08 Angibaud Patrick Rene Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline
EP1408971A4 (en) 2001-06-21 2006-01-25 Ariad Pharma Inc NEW QUINOLINES AND THEIR USES
EP1458720B1 (en) 2001-12-19 2009-03-18 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
EP1490065B1 (en) 2002-03-22 2007-06-13 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
EA009875B1 (ru) * 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Gtpアーゼ阻害剤および使用方法
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559282A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
WO2007016539A2 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
EP1968591A4 (en) 2005-12-23 2010-02-17 Link Medicine Corp TREATMENT OF SYNUCLEINOPATHIES
AU2008256928A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2138844B1 (en) 2008-06-26 2012-04-25 SpheroTec GmbH Method for testing the response of cells to exposures with therapeutics
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
ES2619610T3 (es) 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
HUE044698T2 (hu) 2015-08-17 2019-11-28 Kura Oncology Inc Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー, インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP4119142A1 (en) 2017-02-21 2023-01-18 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MY200746A (en) 2017-08-07 2024-01-13 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
TW202031259A (zh) 2018-11-01 2020-09-01 美商庫拉腫瘤技術股份有限公司 以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
AU2020254492A1 (en) 2019-03-29 2021-11-11 Kura Oncology, Inc. Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
WO2020205387A1 (en) 2019-04-01 2020-10-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CA3151110A1 (en) 2019-08-16 2021-02-25 Children's Hospital Medical Center Methods of treating a subject with a cdc42-specific inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
CA2251716A1 (en) * 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
WO1998002436A1 (en) * 1996-07-15 1998-01-22 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
PL193464B1 (pl) 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
SK11002001A3 (sk) * 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky

Also Published As

Publication number Publication date
NO20010082D0 (no) 2001-01-05
CN1152716C (zh) 2004-06-09
KR100591603B1 (ko) 2006-06-20
IL140721A (en) 2008-11-26
AU4780599A (en) 2000-01-24
JP2002519389A (ja) 2002-07-02
HUP0103689A2 (hu) 2002-02-28
CA2336624C (en) 2008-10-21
DE69907461D1 (de) 2003-06-05
CN1311692A (zh) 2001-09-05
BG64941B1 (bg) 2006-10-31
HK1034451A1 (en) 2001-10-26
HU229076B1 (en) 2013-07-29
TW586937B (en) 2004-05-11
CA2336624A1 (en) 2000-01-13
MY126519A (en) 2006-10-31
AU762423B2 (en) 2003-06-26
EP1094839B1 (en) 2003-05-02
SK19862000A3 (sk) 2001-12-03
EP1094839A1 (en) 2001-05-02
WO2000001411A1 (en) 2000-01-13
AP1599A (en) 2006-04-27
EA200100111A1 (ru) 2001-06-25
CZ20004777A3 (en) 2001-05-16
PT1094839E (pt) 2003-09-30
ATE238811T1 (de) 2003-05-15
BR9911861A (pt) 2001-03-20
DK1094839T3 (da) 2003-08-18
ES2199579T3 (es) 2004-02-16
SK284723B6 (sk) 2005-10-06
US6545020B1 (en) 2003-04-08
HRP20000903A2 (en) 2001-12-31
NO328178B1 (no) 2009-12-28
DE69907461T2 (de) 2004-02-19
CZ300968B6 (cs) 2009-09-30
KR20010052770A (ko) 2001-06-25
AP2001002057A0 (en) 2001-03-31
PL347979A1 (en) 2002-05-06
EE200000794A (et) 2002-06-17
HUP0103689A3 (en) 2003-01-28
BG105108A (en) 2001-11-30
EA003877B1 (ru) 2003-10-30
TR200003879T2 (tr) 2007-01-22
ID26987A (id) 2001-02-22
SI1094839T1 (en) 2003-12-31
IL140721A0 (en) 2002-02-10
NO20010082L (no) 2001-01-05
PL193464B1 (pl) 2007-02-28
JP4530537B2 (ja) 2010-08-25

Similar Documents

Publication Publication Date Title
EE200000794A (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis
EE04579B1 (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
HUP0200403A3 (en) Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their use
EE200200622A (et) Aromataasi inhibiitori kasutamine farmatseutilisekompositsiooni valmistamiseks, mis on ette nähtudHER2 valgu liigse avaldumisega hormoon-sõltuva häire raviks, ja meetod vähivastase ravi kõrvaltoimete vähendamiseks
ID30460A (id) Inhibitor-inhibitor protein siklik tirosin kinase
AU7490700A (en) Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
HUP0202490A3 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
MY117961A (en) Inhibitors of farnesyl protein transferase
WO2002028832A3 (en) Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
NO973608D0 (no) Nye farnesyl-transferaseinhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene
HUP0203054A3 (en) Farnesyl protein transferase inhibitors, pharmaceutical compositions containing them and their use
TR200100054T2 (tr) Paroksetin metansülfonat
EP1165084A4 (en) INHIBITORS OF PRENYL PROTEIN TRANSFERASES
NO985368L (no) Substituerte imidazolidinderivater, deres fremstilling, deres anvendelse og farmas°ytiske preparater inneholdende forbindelsene
EE03858B1 (et) Konjugaadid, nende kasutamine eesnäärmevähi ravimites, farmatseutiline kompositsioon ja selle valmistamine
ZA9711734B (en) Novel farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments.
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
NO20005680D0 (no) Kombinasjoner av protein-farnesyltransferase og HMG CoA reduktase inhibitorer og anvendelse derav for behandling av cancer
EE200200605A (et) Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks
FI953934L (fi) Farnesyyli:proteiinitransferaasin inhibiittoreja, jotka toimivat syöpää vastaan vaikuttavina aineina
NO304230B1 (no) Piperazinforbindelse, medikament og farmas°ytisk preparat omfattende denne
EP1158983A4 (en) Prenyl protein transferase inhibitors
EE200100082A (et) Taksoidi derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud rakkude ebaloomuliku proliferatsiooni raviks laiaspektrilise ravimresistentsusega P-glükoproteiini ekspresseerivates rakuliinides
HK1063748A (en) Use of an farnesyl protein transferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
NZ509646A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231